Frankfurt
23.12.24
08:16 Uhr
1,346 Euro
-0,018
-1,32 %
-1,32 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | DIAMYD MEDICAL AB: Renowned Diabetes Investigator, Emily Sims, Joins Diamyd Medical's Scientific Advisory Board | 1 | Cision News | ||
| 13.12. | Diamyd Medical AB: Diamyd Medical Aligns with FDA on Key Elements for an Accelerated Approval Process | 286 | PR Newswire | STOCKHOLM, Dec. 13, 2024 /PRNewswire/ -- Diamyd Medical today announced a positive in-person Type C meeting with the U.S. Food and Drug Administration (FDA), where alignment was achieved... ► Artikel lesen | |
| 05.12. | Bulletin from Annual General Meeting of Diamyd Medical AB | 2 | Cision News | ||
| 03.12. | DIAMYD MEDICAL AB: Annual Report 2023/2024 | 2 | Cision News | ||
| 25.11. | DIAMYD MEDICAL AB: Article published by ASSET, coordinated by Diamyd Medical, advocates for national screening programs in Sweden for early detection of Type 1 Diabetes | 1 | Cision News | ||
| 21.11. | Diamyd Medical AB: Diamyd Medical hits a recruitment milestone in DIAGNODE-3 Phase 3 trial | 197 | PR Newswire | STOCKHOLM, Nov. 21, 2024 /PRNewswire/ -- 180 patients have now been recruited in the precision medicine Phase 3 trial DIAGNODE-3, exceeding the recruitment target set for the planned early... ► Artikel lesen | |
| 15.11. | DIAMYD MEDICAL AB: Conference on the future of Type 1 Diabetes screening organized as part of the ASSET partnership coordinated by Diamyd Medical | 1 | Cision News | ||
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 14.11. | DIAMYD MEDICAL AB: Diamyd Medical recognizes World Diabetes Day | 1 | Cision News | ||
| 14.11. | DIAMYD MEDICAL AB: Information about the Annual Report 2023/2024 | 2 | Cision News | ||
| 06.11. | Diamyd Medical AB: In-depth analysis showing robust Diamyd treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress | 278 | PR Newswire | STOCKHOLM, Nov. 6, 2024 /PRNewswire/ -- (IDS) Congress in Bruges, Belgium. The analysis will be presented at a Satellite Symposium organized by Abbott. The results support the robustness... ► Artikel lesen | |
| 06.11. | DIAMYD MEDICAL AB: In-depth analysis showing robust Diamyd[®] treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress | 2 | Cision News | ||
| 05.11. | DIAMYD MEDICAL AB: Diamyd Medical and INNODIA partner for Type 1 Diabetes awareness and patient recruitment for the DIAGNODE-3 precision medicine trial | 1 | Cision News | ||
| 14.10. | DIAMYD MEDICAL AB: Diamyd Medical highlights precision medicine approach for Type 1 Diabetes at the scientific conferences ISPAD and IDS | 1 | Cision News | ||
| 09.10. | Diamyd Medical AB (publ): Year-End Report 23/24 | 97 | GlobeNewswire (Europe) | September 2023 - August 2024, Diamyd Medical AB (publ), Fiscal year 2023/2024
Precision Medicine for Autoimmune Diabetes
Aiming for Accelerated Market Approval
Diamyd Medical's B-share is traded on... ► Artikel lesen | |
| 02.10. | DIAMYD MEDICAL AB: Diamyd Medical announces final outcome of the exercise of series TO 3 warrants | 1 | Cision News | ||
| 25.09. | DIAMYD MEDICAL AB: The last day of trading in Diamyd Medical's warrants of series TO 3 is today | 1 | Cision News | ||
| 09.09. | Diamyd Medical AB: Diamyd Medical to pursue accelerated approval pathway for Type 1 Diabetes precision medicine | 349 | PR Newswire | STOCKHOLM, Sept. 9, 2024 /PRNewswire/ -- Diamyd Medical will pursue an accelerated approval pathway in the U.S. for its antigen-specific immunotherapy, Diamyd® (rhGAD65/alum), aimed at preserving... ► Artikel lesen | |
| 02.09. | DIAMYD MEDICAL AB: The exercise period for Diamyd Medical's warrants of series TO 3 begins today | 2 | Cision News | ||
| 30.07. | Diamyd Medical AB: Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes | 473 | PR Newswire | STOCKHOLM, July 30, 2024 /PRNewswire/ -- Diamyd Medical today announced a successful interim analysis (non-futility test) for its ongoing precision medicine Phase 3 DIAGNODE-3 trial. The... ► Artikel lesen | |
| 23.07. | Diamyd Medical AB: Diamyd Medical receives positive feedback from FDA on potential Accelerated Approval for Diamyd® in Type 1 Diabetes | 273 | PR Newswire | STOCKHOLM, July 23, 2024 /PRNewswire/ -- Diamyd Medical received encouraging feedback from the U.S. Food and Drug Administration (FDA) regarding an Accelerated Approval pathway for its immunotherapy... ► Artikel lesen |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 171,00 | -0,24 % | PTA-News: Small- & MicroCap Investment: Mehr Potenzial als Eli Lilly oder AbbVie? Analysten mit Top-Prognosen für NurExone | DJ PTA-News: Small- & MicroCap Investment: Mehr Potenzial als Eli Lilly oder AbbVie? Analysten mit Top-Prognosen für NurExone
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt (pta/22.12.2024/10:30)... ► Artikel lesen | |
| ABBOTT LABORATORIES | 109,12 | -0,66 % | Abbott, Dexcom settle global CGM patent litigation | ||
| ZOETIS | 158,16 | +0,15 % | Zoetis-Aktie: Kurs nur geringfügig im Minus (165,1123 €) | Wenig Kursbewegung gegenwärtig bei dem Anteilsschein von Zoetis . Der jüngste Kurs betrug 174,74 US-Dollar. Kaum verändert im Vergleich zu der letzten Notierung des vorigen Handelstages zeigt sich zur... ► Artikel lesen | |
| CASSAVA SCIENCES | 2,317 | -0,13 % | XFRA PX91: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 81,86 | -2,03 % | Axsome Therapeutics Aktie: Aufwärtskurs setzt sich fort! | Die Axsome Therapeutics Aktie verzeichnete am 07. Dezember 2024 einen marginalen Rückgang von 0,02 Prozent und notierte bei 94,57 EUR. Trotz des leichten Tagesverlusts zeigt der Biotech-Wert eine robuste... ► Artikel lesen | |
| WUXI BIOLOGICS | 2,187 | +1,74 % | WuXi Biologics and Hangzhou DAC sign ADC agreement | ||
| ACADIA PHARMACEUTICALS | 16,200 | -1,91 % | Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview | SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024.
"The success of Acadia's two growing... ► Artikel lesen | |
| DAIICHI SANKYO | 26,650 | -0,63 % | Astrazeneca/Daiichi Sankyo ziehen EU-Zulassungsantrag für Lungenkrebsmittel zurück | DJ Astrazeneca/Daiichi Sankyo ziehen EU-Zulassungsantrag für Lungenkrebsmittel zurück
Von Najat Kantouar
Dow Jones--Die Pharmakonzerne AstraZeneca und Daiichi Sankyo ziehen ihren Antrag auf... ► Artikel lesen | |
| TRULIEVE CANNABIS | 4,748 | +2,42 % | Trulieve Cannabis Aktie: Kein Wachstum erwartet | Der Cannabis-Konzern Trulieve verzeichnet zum Jahresende eine markante Kurskorrektur an den Börsen. Mit einem aktuellen Aktienkurs von 4,624 EUR zeigt das Unternehmen eine beachtliche monatliche Einbuße... ► Artikel lesen | |
| TG THERAPEUTICS | 31,090 | +6,33 % | TG Therapeutics, Inc.: New Data for BRIUMVI (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment | During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 26,750 | +0,22 % | Bayer-Partner BridgeBio Pharma: Meilenstein - EU-Zulassung zum Greifen nah | Im November hat BridgeBio Pharma erst für Attruby (Acoramidis) die Zulassung von der US-Gesundheitsbehörde FDA erhalten. Und auch in Europa ist das Biotech-Unternehmen mit seinem dortigen Partner Bayer... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,450 | -1,45 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE in Japan | CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| WEST PHARMACEUTICAL SERVICES | 315,80 | -0,25 % | Looking Into West Pharmaceutical Services' Recent Short Interest | ||
| CNBX PHARMACEUTICALS | - | - | CNBX Pharmaceuticals Inc. - 10-K, Annual Report | ||
| AURINIA PHARMACEUTICALS | 8,600 | +0,09 % | Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development | ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months... ► Artikel lesen |
Das Unternehmen DIAMYD MEDICAL AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,32 % bei einem Aktienkurs von 1,346 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.
